Search
Powered By HealthLine
Special Offers
Health Tools
 Neurology Health Center
 Understanding Multiple Sclerosis
 Fibromyalgia Basics
 Video: Alzheimer's Disease
 Migraine - What is it?
Featured Conditions
 Alzheimer's
 Chronic Pain
 Multiple Sclerosis
 Depression
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today



Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine| Drug Checker
 Printer Friendly  Send to a Friend

PET Imaging in Question

Ivanhoe Newswire


Related Encyclopedia
 border=
Acoustic Neurinoma
Bell's Palsy
Brain and Spinal Cord Magnetic Resonance Imaging
Brain Tumors
More...

Related Healthscout Videos
 border=
New Drugs That Could Stop MS
New Therapy for Stroke Patients
Mapping the Brain     
Hope for MS
More...

Related Drug Information
 border=
Adderal XR
Concerta
Coumadin
Depakote
More...

Related News Articles
 border=
Prostate Cancer Stimulates Nerve Growth
Memory Formation Different in Those With Stress-Related Psychiatric Disorders
Epilepsy Drug May Raise Autism Risk in Offspring
Exercise Eases Depression and Heart Disease
More...

(Ivanhoe Newswire) -- The value of positron emission tomography with a radioactive tracer (FDG-PET) is in question after the results of a new study show it isnt effective in detecting small metastases in patients with head and neck cancer.

To form a prognosis for head and neck squamous cell cancers, doctors need to know if it has spread to nearby lymph nodes. While a patient may seem to be clinically clean, he may actually have small metastases. The standard testing includes using MRI (magnetic resonance imaging), CT (commuted tomography) and FDG-PET to detect small lesions.

Text Continues Below



Researchers from the University of Ioannina School of Medicine in Greece analyzed previously published studies that tested the performance of FDG-PET and found it failed to detect small lesions 50 percent of the time in node negative patients. It also misidentified normal tissue as being cancerous 13 percent of the time.

In addition, the researchers compared the sensitivity of FDG-PET with MRI and CT and found a trend for small improvement in detecting with FDG-PET, but nothing statistically significant.

The researchers concluded there was not enough evidence to support routine use of FDG-PET in patients with head and neck squamous cell cancer.

David L. Schwartz, M.D., a radiation oncologist at the University of Texas M.D. Anderson Cancer Center in Houston, and some of his colleagues disagree. In an accompanying editorial, they note the studies done so far have been single institutions and that no large randomized trials have looked at the issue. They also note clinicians rely on a variety of imaging techniques in addition to examinations. Comparing one imaging technique against another may not adequately capture the possible benefit gained from an approach, the researchers wrote.

Sign up for a free weekly e-mail on Medical Breakthroughs called First to Know by clicking here.

SOURCE: Journal of the National Cancer Institute, published online May 13, 2008


 

This article was reported by Ivanhoe.com, who offers Medical Alerts by e-mail every day of the week. To subscribe, go to: http://www.ivanhoe.com/newsalert/.




Last updated 5/14/2008

Related Links
 border=
From Healthscout's partner site on chronic pain, ChronicPainConnection.com
Find ways to get chronic pain relief!
Find a right treatment for your chronic pain
Join our community - your chronic pain support group.






We comply with the HONcode standard for trustworthy health
information:
verify here.
About The HealthScout Network Contact Us
Copyright © 2001-2008. The HealthCentralNetwork, Inc. All rights reserved.
Privacy Policy  Terms of Service